SCHEMBL2102355

SCHEMBL2102355

CCC([SiH3])c1cccc(Cl)c1Cl

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PNMT P11086 2/20 0.52
CYP1A2 P05177 1/20 0.52
CYP3A4 P08684 1/20 0.52
CYP2D6 P10635 1/20 0.52
NFKB1 P19838 1/20 0.52
ALDH1A1 P00352 1/20 0.50
LMNA P02545 1/20 0.50
GLA P06280 1/20 0.50
TAS1R3 Q7RTX0 1/20 0.40
TAS1R1 Q7RTX1 1/20 0.40
TAS1R2 Q8TE23 1/20 0.40
IDO1 P14902 2/20 0.39
TDO2 P48775 1/20 0.39
MEN1 O00255 1/20 0.38
KMT2A Q03164 1/20 0.38
DRD2 P14416 3/20 0.36
DRD3 P35462 3/20 0.36
KCNH2 Q12809 1/20 0.36
TSHR P16473 1/20 0.35
TAAR1 Q96RJ0 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15302604 0.85 PNMT (0.53) PNMTCYP1A2CYP3A4CYP2D6NFKB1
SCHEMBL2272069 0.83 NISCH (0.44) PNMTCYP1A2CYP3A4CYP2D6NFKB1
SCHEMBL15302813 0.82 PNMT (0.46) PNMTCYP1A2CYP3A4CYP2D6NFKB1
SCHEMBL9770072 0.79 PNMT (0.55) PNMTCYP1A2CYP3A4CYP2D6NFKB1
SCHEMBL2632878 0.79 PNMT (0.55) PNMTCYP1A2CYP3A4CYP2D6NFKB1
SCHEMBL2102181 0.78 CXCL8 (0.35) PNMTCYP1A2CYP3A4CYP2D6NFKB1
SCHEMBL2102663 0.78 NISCH (0.38) PNMTCYP1A2CYP3A4CYP2D6NFKB1
SCHEMBL2632877 0.78 PNMT (0.59) PNMTCYP1A2CYP3A4CYP2D6NFKB1
SCHEMBL15302407 0.77 CYP1A2 (0.63) PNMTCYP1A2CYP3A4CYP2D6NFKB1
SCHEMBL2102669 0.77 CYP1A2 (0.33) PNMTCYP1A2CYP3A4CYP2D6NFKB1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8791221-B2 Addition-curable metallosiloxane compound DAICEL CORPORATION (JP) 2014-07-29 US disclosed
EP-2650319-A1 ADDITION-CURABLE METALLOSILOXANE COMPOUND Daicel Corporation (JP) 2013-10-16 EP disclosed
US-20130267653-A1 ADDITION-CURABLE METALLOSILOXANE COMPOUND DAICEL CORPORATION (JP) 2013-10-10 US disclosed
US-8404584-B2 Method of manufacturing semiconductor device FUJITSU LIMITED (JP) 2013-03-26 US disclosed
US-8164166-B2 Interfacial roughness reducing film, wiring layer, semiconductor device, and method of manufacturing semiconductor device FUJITSU LIMITED (JP) 2012-04-24 US disclosed
US-20110207319-A1 METHOD OF MANUFACTURING SEMICONDUCTOR DEVICE FUJITSU LIMITED (JP) 2011-08-25 US disclosed
US-20090085170-A1 INTERFACIAL ROUGHNESS REDUCING FILM, WIRING LAYER, SEMICONDUCTOR DEVICE, AND METHOD OF MANUFACTURING SEMICONDUCTOR DEVICE FUJITSU LIMITED (JP) 2009-04-02 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130267653-A1 ADDITION-CURABLE METALLOSILOXANE COMPOUND B2M, MSI2, MNS1 PNMT 1722/4885CYP1A2 3597/4885CYP3A4 4160/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.